(https://news.google.com/rss/articles/CBMiswFBVV95cUxPVU43TjhlMUUzTzFVU2Rja1JkNXdvTWNqTHNINmtCU2RzMzR1MGtMdU5abks3eDN3aEtMeWV0VjdERGFwU1RGZGZwNzQzRDQ1RXZlYVpfc3VGN0pmLWpFREE1NXpJMHFsWU5SZExJQ2tNTUZ2MWFzcWxUalFBRjlrS2k4c1FUYjJteVRDUGFYLS1lb0c3ZHVYTnVaNTI3alEyOXRTVVBicHlJR2k4TmN0ZG1zbw?oc=5) while Novo gets crushed on a failed heart drug trial tells you the sector's bifurcating hard. ABBV's Botox revival is real, but that's legacy cash generation—not growth.

Research these companies